Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients

BACKGROUND: The World Health Organisation recommended dolutegravir (DTG)-based antiretroviral therapy (ART) regimens are available but not reimbursed through the public reimbursement system in China. The objective of this analysis was to evaluate the cost-effectiveness of DTG (DTG + TDF/3TC) compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Punekar, Yogesh Suresh, Guo, Na, Tremblay, Gabriel, Piercy, James, Holbrook, Tim, Young, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896323/
https://www.ncbi.nlm.nih.gov/pubmed/31827410
http://dx.doi.org/10.1186/s12962-019-0195-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896323/
https://www.ncbi.nlm.nih.gov/pubmed/31827410
http://dx.doi.org/10.1186/s12962-019-0195-2

Ejemplares similares